LinkOPH

BOSTON — Vitrectomized eyes fared as well as non-vitrectomized eyes after treatment with ranibizumab for diabetic macular edema, according to a study presented at Macula 2015.“The efficacy of ranibizumab in the treatment of diabetic retinopathy is well established, but there remain some uncertainties in clinical management with ranibizumab for DME,” Jack Wells, MD,said. “There’s a common clinical impression that the duration of action of anti-VEGF injected in eyes with prior vitrectomy would be shorter than in eyes without prior vitrectomy due to more rapid clearing of the drug, and therefore (Read more...)

NEW YORK – Robert Noecker, MD, gives his pearls on adopting minimally invasive glaucoma surgery.

Read more →

BOSTON — Among “lessons learned” from the VIVID and VISTA trials is that aflibercept is an effective treatment for patients with center-involved diabetic macular edema, according to one presenter at Macula 2015.“The totality of the evidence suggests that aflibercept is a very effective and safe treatment for our patients with DME,” Diana V. Do, MD, said at Macula 2015, adding that the diabetic retinopathy severity score improves with use of the drug as well.

Read more →